Darunavir / Ritonavir + Tenofovir / Emtricitabine — Competitive Intelligence Brief

Darunavir / Ritonavir + Tenofovir / Emtricitabine (Darunavir / Ritonavir + Tenofovir / Emtricitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors). Area: Infectious D

marketed Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease, HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Darunavir / Ritonavir + Tenofovir / Emtricitabine (Darunavir / Ritonavir + Tenofovir / Emtricitabine) — Juan A. Arnaiz. This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Darunavir / Ritonavir + Tenofovir / Emtricitabine TARGET	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Atazanavir + Ritonavir + 2 NRTIs	Atazanavir + Ritonavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) class)

1. Juan A. Arnaiz · 1 drug in this class
2. ViiV Healthcare · 1 drug in this class